Abstract
A survey of the literature shows that the experience with radiotherapy (RT) in the local treatment of osteosarcoma (OS) is limited. This is due to various reasons: OS is a rare tumor and surgery is the treatment of choice with high local control rate, and uncertainty exists in regard to the efficacy and tolerance of radiotherapy. Publications on this topic were analyzed and will be reviewed. Furthermore, experience from the Cooperative Osteosarkomstudiengruppe (COSS)-Registry, including 100 patients (pts) treated using radiotherapy for OS, was analyzed.
The COSS-registry includes a total of 175 pts (5% of all pts) with histologically proven OS irradiated over the period of 1980−2007. 100 pts were eligible for analysis. The median age was 18 (3–66) years. Indication for RT was a primary tumor in 66, a local recurrence in 11, and metastases in 23 pts. 94 pts got external photontherapy; 2 pts, proton therapy; 2 pts, neutron therapy; and 2 pts, intraoperative RT. In addition, a group of 17 pts received bone-targeted radionuclide therapy by samarium-153-EDTMP-therapy alone or in combination with external RT. The median dose for external RT was 55.8 Gy (30–120). All the pts received chemotherapy in accordance with different COSS-protocols.
The median follow-up was 1.5 (0.2–23) years. Survival and local control rates at 5 years were calculated, and univariate and multivariate analyses performed. 41 pts are alive, 59 pts died. The overall survival rate after biopsy was 41% at 5 years, while the overall survival rates after RT for the whole group, for treatment of primary tumors, local recurrence, and metastases were 36%, 55%, 15%, and 0% respectively.
In 41 cases, local control was achieved, whereas local progression or local recurrence occurred in 59 cases, with a median time to local recurrence of 0.5 (0.1–4) years after RT. 15 pts were nonresponders to radiotherapy. Local control for the whole group was 30%. Local control rates for combined surgery and RT were significantly better than those for RT alone (48% vs. 22%, p=0.002). Local control for treatment of primary tumors, local recurrence, and metastases were 40%, 17%, and 0% respectively. Local control for pts given an addition of samarium-153-EDTMP was poor, though not statistically significant . A dose of over 60 Gy had no significant effect on local control. Prognostic factors for survival were indication for RT, RT plus surgery vs. RT alone and tumor location. Prognostic factors for local control were indication for RT, and RT plus surgery vs. RT alone.
For the majority of pts, surgery remains the local treatment of choice. Radiotherapy is an important option as local treatment of unresectable tumors, following intralesional resection, or as palliation of symptomatic metastases. Survival prognosis of such pts, however, is poor. Despite the fact that many of these pts will eventually die, they may benefit in terms of prolonged survival and prolonged local control. The combination of surgery, radiotherapy, and chemotherapy can be curative. The consistent use of full-dose chemotherapy is of importance for the response to radiotherapy. Prognostic factors for survival are indication for RT, RT plus surgery vs. RT alone and tumor location. Prognostic factors for local control are indication for RT, and RT plus surgery vs. RT alone.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Paediatr. 1999;211:260-270.
Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292-315.
Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76-84.
Weis LD. The success of limb-salvage surgery in the adolescent patient with osteogenic sarcoma. Adolesc Med. 1999;10:451-458.
Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma: the University of Muenster experience. Clin Orthop. 1999;358:83-89.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative oseosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcomas of the extremities. Ann Oncol. 1997;8:899-903.
Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the cooperative osteosarcoma study group. J Clin Oncol. 2003;21:334-341.
Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the cooperative osteosarcoma study group. Cancer. 2002;94:1069-1077.
Kassir RR, Rassekh CH, Kinsella JB, et al. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies. Laryngoscope. 1997;107:56-61.
Jenkin RD, Allt W, Fitzpatrick PJ. Osteosarcoma: an assessment of management with particular reference to primary irradiation and selective delayed amputation. Cancer. 1972;2:393-400.
De Moor NG. Osteosarcoma: a review of 72 cases treated by megavoltage radiation therapy, with or without surgery. S Afr J Surg. 1975;13:137-146.
Beck JC, Wara WM, Bovill EG Jr, et al. The role of radiation therapy in the treatment of osteosarcoma. Radiology. 1976;120:163-165.
Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1:79-111.
Gaitan-Yanguas M. A study of the response of osteogenic sarcoma and adjacent normal tissues to radiation. Int J Radiat Oncol Biol Phys. 1981;7:593-595.
Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 2003;78:147-155.
DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Rad Oncol Biol Phys. 2005;61:492-498.
Bruland ØS, Skretting A, Solheim ØP, et al. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncologica. 1996;35:381-384.
Bruland ØS, Skretting A, Saeter G, et al. Targeted internal radiotherapy in osteosarcoma patients using 153Sm-EDTMP. Med Ped Oncol. 1996;27:215.
Bruland ØS, Phil A. On the current management of osteosarcoma: a critical evaluation and proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725-1731.
Anderson PM, Wisemann GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamnine tetramethylene phosphonate phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:189-196.
Franzius C, Bielack S, Sciuk J, et al. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38:337-340.
Franzius C, Schuck A, Bielack SS. High-dose Samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:1953-1954.
Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma Relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol. 2005;23:559-568.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996;50:163-170.
Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B). 1972;34:187-220.
Larsen RH, Bruland ØS, Hoff Å, et al. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody; comparison with Astatine-21-labelled bovine serum albumon, free Astatine-211 and external-beam X rays. Rad Res. 1994;139:178-184.
Larsen RH, Bruland ØS, Hoff P, et al. Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibodies. Br J Cancer. 1994;69:1000-1005.
Olsen DR, Bruland ØS. Is osteosarcoma a radioresistant tumor? Towards the Eradication of Osteosarcoma Metastases – An Odyssey. The Norwegian Radium Hospital; 1998:73–76.
Sundaresan N, Rosen G, Ag H, et al. Combined treatment of osteosarcoma of the spine. Neurosurgery. 1988;23:714-719.
Caceres E, Zaharia M, Valdivia S, et al. Local control of osteogenic sarcoma by radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1984;10:35-39.
Lombardi F, Gandola L, Fossati-Belani F, et al. Hypofractionated accelerated radiotherapy in osteogenic sarcoma. Int J Rad Oncol Biol Phys. 1992;24:761-765.
Calvo FA, Ortiz de Urbina D, Sierrasesumaga L, et al. Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents. Med Pediatr Oncol. 1991;19:478-485.
Hong A, Stevens G, Stalley P, et al. Extracorporeal irradiation for malignant bone tumors. Int J Radiat Oncol Biol Phys. 2001;50:441-447.
Oya N, Kokubo M, Mizowaki T, et al. Definitive intraoperative very high-dose radiotherapy for localized osteosarcoma in the extremities. Int J Radiat Oncol Biol Phys. 2001;51:87-93.
Sabo D, Bernd L, Buchner M, et al. Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors. Orthopäde. 2003;32:1103-1112.
Uhl V, Castro JR, Knopf K, et al. Preliminary results in heavy charged particle irradiation of bone sarcoma. Int J Radiat Oncol Biol Phys. 1992;24:755-759.
Castro JR, Linstadt DE, Bhary JP, et al. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys. 1994;29:647-655.
Hug EB, Munzenrieder JE. Charged particle therapy for base of skull tumors: Past accomplishments and future challenges. Int J Radiat Oncol Biol Phys. 1994;29:911-919.
Kamada T, Tsujii H, Tsuji H, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20:4466-4471.
Chambers RG, Mahoney WD. Osteogenic sarcoma of the mandible, current management. Am Surg. 1970;36:463-471.
Eilber FR, Morton DL, Eckhardt J, et al. Limb salvage for skeletal and soft tissue sarcomas: multidisciplinary preoperative therapy. Cancer. 1984;53:2579-2584.
Dincbas FO, Koca S, Mandel NM, et al. The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int J Radiat Oncol Biol Phys. 2005;62:820-828.
Carrie C, Breteau N, Negrier S, et al. The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report. Med Pediatr Onco. 1994;22:355-357.
Burgers JM, van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs. Report of the EORTC-SIOP03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer. 1988;61:1024-1031.
Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol. 2002;13:23-30.
Appelbaum FR, Sandmaier B, Brown PA, et al. Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Imunoconjug Radiopharm. 1988;1:263-270.
Turner JH, Claringbold PG, Heytherington EL. A phase I study of samarium 153 ethylene diamine tetramethylene phosphonate therapy for dissiminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931.
Turner JH, Martindale AA, Sorby P. Samarium 153EDTMP therapy of dissiminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-795.
Franzius C, Bielack S, Sciuk J, et al. High-activity samarium-EDTMP therapy followed by autologues peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001;40:215-220.
Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of Osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer. 2007;. doi:10.1002/pbc.21451.
Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin Proc. 2003;78:145-146.
Jaffe N, Knapp J, Chuang VP, et al. Osteosarcomas: Intra-arterial treatment of the primary tumor with Cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51:402-407.
Kinsella TJ, Glatstein E. Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer. 1987;59:908-915.
Estrada-Aguilar J, Greenberg H, Walling A, et al. Primary treatment of pelvic osteosarcoma. Cancer. 1992;69:1137-1145.
Martinez A, Goffinet DR, Donaldson SS, et al. Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. Int J Radiat Oncol Biol Phys. 1985;11:123-128.
Anderson PM (2002) Samarium + gemcitabine concept. Presented at: Children’s Oncology Group meeting; October 26, St. Louis, Mo.
Anderson P, Aguilera D, Pearson M, et al. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control. 2008;15:38-46.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Schwarz, R., Bruland, O., Cassoni, A., Schomberg, P., Bielack, S. (2009). The Role of Radiotherapy in Oseosarcoma. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_7
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)